

INVESTOR FACT SHEET

AT-A-GLANCE

Skystar is a leading manufacturer and distributor of veterinary medicines and healthcare products in China. Supplying both Traditional Chinese Medicine (TCM) and Western Medicine; the Company provides a comprehensive suite of veterinary products serving regional micro-farms offering:


- Veterinary vaccines including aquaculture
- Veterinary medicines
- Pro-biotic microorganisms
- Animal feed additives

Headquartered in Xi'an, Shaanxi Province, Central China, Skystar is the only US-listed pure play in the China animal health sector. Skystar's China GMP certified production facilities and processes is regulated by China's State Food and Drug Administration (SFDA) under China's Ministry of Health.


INVESTMENT HIGHLIGHTS

- Four manufacturing facilities
- GMP Compliance barrier to new entry
- Proxy to China's changing consumption trends
- Strong financial position and historical performance
- Proven track record for growing the Company profitably
- 100+ drugs and formularies under license, renewable every 5 years
- Potential industry consolidator in a fragmented market
- After sales training and technical support for customers
- Expansive sales and distribution network across all 29 farm producing provinces in China


Historical Annual Revenue



Historical Gross Profit / Gross Margins



Revenues By Offering



MANAGEMENT

Weibing Lu - Chairman and CEO
 Bing Mei - Chief Financial Officer
 Scott Cramer – Director Corporate Development and U.S. Rep.

CONTACT INFO:

Skystar Headquarters (China)
 Rm. 10601, Jiezu Plaza, No. 4, Fenghui Road South, Gaoxin District, Xi'an, Shaanxi Province, P.R.China

T: +86 (29) 8819-3188

Director Corporate Development and U.S. Representative
 Scott Cramer, Director

T: + 1 (407) 645-4433

E: scramer@skystarbio-pharmaceutical.com

Investor Relations

Grayling

Christopher Chu, Director
 102 Madison Avenue, New York, NY 10016
 T: +1 (646) 284-9426 | E: christopher.chu@grayling.com

